After the failure of an experimental drug for Angelman syndrome, experts cautioned that there is still reason to think similar experimental medicines can succeed.
The FDA has issued a request for information on botanical drug products.
Acting Commissioner Kyle Diamantas said that the agency is hoping to evaluate “natural health options” to offer new therapies “while maintaining the highest safety standards."
